Risk factors for alloimmunization by patients with sickle cell disease

被引:51
作者
Murao, M
Viana, MB
机构
[1] Univ Fed Minas Gerais, Hosp Clin, Fdn Hemominas, Belo Horizonte, MG, Brazil
[2] Univ Fed Minas Gerais, Hosp Clin, Dept Pediat, Hematol Serv, Belo Horizonte, MG, Brazil
关键词
sickle cell disease; red cell alloimmunization; blood cell transfusion; transfusion reactions;
D O I
10.1590/S0100-879X2005000500004
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Blood transfusion in patients with sickle cell disease (SCD) is limited by the development of alloantibodies to erythrocytes. In the present study, the frequency and risk factors for alloimmunization were determined. Transfusion records and medical charts of 828 SCD patients who had been transfused and followed at the Belo Horizonte Blood Center, Belo Horizonte, MG, Brazil, were retrospectively reviewed. Alloimmunization frequency was 9.9% (95% CI: 7.9 to 11.9%) and 125 alloantibodies were detected, 79% of which belonged to the Rhesus and Kell systems. Female patients developed alloimmunization more frequently (P = 0.03). The median age of the alloimmunized group was 23.3 years, compared to 14.6 years for the non-alloimmunized group (P < 0.0001). Multivariate analyses were applied to the data for 608 hemoglobin (Hb) SS or SC patients whose number of transfusions was recorded accurately. Number of transfusions (P = 0.00006), older age (P = 0.056) and Hb SC (P = 0.02) showed independent statistical associations with alloimmunization. Hb SC patients older than 14 years faced a 2.8-fold higher (95% Cl: 1.3 to 6.0) risk of alloimmunization than Hb SS patients. Female Hb SC patients had the highest risk of developing alloantibodies. In patients younger than 14 years, only the number of transfusions was significant. We conclude that an increased risk of alloimmunization was associated with older patients with Hb SC, specially females, even after adjustments were made for the number of transfusions received, the most significant variable.
引用
收藏
页码:675 / 682
页数:8
相关论文
共 30 条
[1]  
*AABB, 1999, TECHN MAN
[2]  
ANDRADESR, 1999, REV BRASILEIRA ANAL, V31, P195
[3]   Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications [J].
Castro, O ;
Sandler, SG ;
Houston-Yu, P ;
Rana, S .
TRANSFUSION, 2002, 42 (06) :684-690
[4]   RISK OF ALLOIMMUNIZATION AND DELAYED HEMOLYTIC TRANSFUSION REACTIONS IN PATIENTS WITH SICKLE-CELL DISEASE [J].
COX, JV ;
STEANE, E ;
CUNNINGHAM, G ;
FRENKEL, EP .
ARCHIVES OF INTERNAL MEDICINE, 1988, 148 (11) :2485-2489
[5]   Blood transfusion in sickle cell disease [J].
Davies, SC ;
RobertsHarewood, M .
BLOOD REVIEWS, 1997, 11 (02) :57-71
[6]  
FABRON A, 2000, THESIS UNIFESP SAO P
[7]  
FABRON A, 1999, REV PAUL MED, V117, P38
[8]  
HMIDA S, 1994, NOUV REV FR HEMATOL, V36, P363
[9]  
LUBAN NLC, 1989, AM J PEDIAT HEMATOL, V11, P314
[10]  
Mollison PL., 1997, BLOOD TRANSFUSION CL